- •MEDLINE (Ovid), EMBASE, and Cochrane Central Register of Controlled Trials were searched from database initiation (1946 for MEDLINE, 1974 for EMBASE, and 1995 for Cochrane) up until May 2021.
- •Eight studies were included in this review. Patients receiving neoadjuvant chemoradiotherapy with esophagectomy had better overall survival – HR 0.55; 95% CI: 0.49–0.62.
- •Toxicity was similar, between the two treatments.
- •Given the paucity of data and lack of uniform reporting of endpoints, further studies should be conducted.
Purchase one-time access:Academic and Personal
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Epidemiology of esophageal cancer: update in global trends, etiology and risk factors.Clin J Gastroenterol. 2020; 13: 1010-1021https://doi.org/10.1007/s12328-020-01237-x
- Esophageal cancer: epidemiology, pathogenesis and prevention.Nat Clin Practice Gastroenterol Hepatol. 2008; 5: 517-526https://doi.org/10.1038/ncpgasthep1223
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.Ann Oncol. 2016; 27: v50-v57https://doi.org/10.1093/annonc/mdw329
National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers (Version 2.2021). (https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf).
Best LMJ, Mughal M, Gurusamy KS. Non-surgical versus surgical treatment for oesophageal cancer. Cochrane Database Syst Rev 2016;3(3):CD011498-CD011498. (In eng). DOI: 10.1002/14651858.CD011498.pub2.
- RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ. 2019; 366 (In eng): l4898
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of intervention.BMJ. 2016; 355i4919
- Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.J Thorac Cardiovasc Surg. 2018; 155 (In eng): 2710-2721
- Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?.J Gastrointest Surg. 2013; 17 (In eng): 1375-1381
- Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.Int J Radiat Oncol Biol Phys. 2004; 60 (In eng): 1484-1493
- Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.Ann Surg Oncol. 2011; 18 (In eng): 551-558
- Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.Cancer. 2017; 123 (In eng): 3476-3485
- Stage III esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery.Updates Surg. 2018; 70 (In eng): 423-426
- Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.J Clin Oncol. 2005; 23 (In eng): 2310-2317
- Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required?.J Gastrointest Cancer. 2013; 44 (In eng): 277-284
- Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.J Clin Oncol. 2007; 25 (In eng): 1160-1168
- The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent.Surg Today. 2018; 48 (In eng): 632-639
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.Lancet Oncol. 2015; 16 (In eng): 1090-1098
- Randomized study on dose escalation in definitive chemoradiation for patients with locally Advanced Esophageal Cancer (ARTDECO Study).J Clin Oncol. 2021; (In eng)